S&P 500
Nasdaq
Dow Jones
NVDA
AAPL
TSLA
MSFT
BTC-USD
15-min delayed
Live
Home Market News Price Targets Penny Stocks Crypto Economy Commodities Education
Stocks About Contact

Novavax Inc

NVAX XNAS
$10.11 +1.09 (+11.80%) ▲ 15-min delayed
Open
$9.36
High
$10.75
Low
$9.32
Volume
13.35M
Market Cap
$1.66B

About Novavax Inc

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.

Sector: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) Employees: 749 Website →

Key Financials

Period Revenue Net Income EPS
Q1 2026 $139.51M $-9,491,000 $-0.06
FY 2025 $1.12B $440.30M $2.72
Q3 2025 $70.44M $-202,379,000 $-1.25
Q2 2025 $239.24M $106.51M $0.66

Earnings & Analyst Ratings

Next Earnings: Tue, Aug 4, 2026
Calendar →

Related Market News

No specific coverage for NVAX yet. Check out our latest market news or earnings calendar.

Get NVAX Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Novavax Inc.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.